Valuation: BriaCell Therapeutics Corp.

Market Cap 3.43Cr 3.02Cr 2.8Cr 2.57Cr 4.86Cr 328.33Cr 4.96Cr 33Cr 13Cr 161.34Cr 13Cr 13Cr 557.65Cr P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 1.65Cr 1.45Cr 1.34Cr 1.23Cr 2.33Cr 157.49Cr 2.38Cr 16Cr 6.26Cr 77Cr 6.18Cr 6.05Cr 267.49Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-4.48%
1 week+17.14%
Current month+14.87%
1 month+40.26%
3 months-9.04%
6 months-49.91%
Current year-45.61%
1 week 4.84
Extreme 4.84
5.64
1 month 3.81
Extreme 3.81
5.64
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
28.3
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 65 16/02/2022
Director TitleAgeSince
Director/Board Member 70 01/11/2016
Chairman 41 24/04/2019
Director/Board Member 74 07/03/2019
Date Insider Type Main position Quantity % Market Cap.
19/02Option

Chief Financial Officer

30,000 0.4830%
19/02Option

Chief Technology Officer

30,000 0.4830%
19/02Option

Chairman

53,000 0.8533%
Change 5-day change 1-year change 3-year change Capi.($)
-4.48%+17.14%-80.90%-99.58% 3.43Cr
-2.48%-3.13%+55.85%+89.65% 5.49TCr
-0.55%-8.57%+58.09%+124.47% 5.46TCr
-5.60%-2.20%+11.16%+437.37% 2.51TCr
-1.55%-7.66%-20.21%-17.37% 2.31TCr
-1.69%-0.64%+40.04%-0.48% 1.99TCr
+1.87%+1.87%+38.13%-26.14% 1.75TCr
-2.72%-0.60%+187.08%+351.91% 1.65TCr
-2.42%+1.00%+48.24%+635.77% 1.57TCr
-0.81%+0.34%+24.92%+189.31% 1.42TCr
Average -2.04%+1.53%+36.24%+168.49% 2.42TCr
Weighted average by Cap. -1.81%-1.56%+48.48%+166.86%

Financials

2024 2025
Net sales - -
Net income -47.91L -42.1L -39.04L -35.9L -67.78L -46Cr -69.28L -4.65Cr -1.82Cr -23Cr -1.8Cr -1.76Cr -78Cr -2.63Cr -2.31Cr -2.14Cr -1.97Cr -3.72Cr -251.59Cr -3.8Cr -26Cr -10Cr -123.63Cr -9.88Cr -9.66Cr -427.32Cr
Net Debt -9L -8L -7L -6L -12.2L -8.24Cr -12.46L -83.73L -32.78L -4.05Cr -32.37L -31.66L -14Cr -1.79Cr -1.57Cr -1.46Cr -1.34Cr -2.53Cr -170.84Cr -2.58Cr -17Cr -6.79Cr -84Cr -6.71Cr -6.56Cr -290.16Cr
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
13/26/13 CA$5.330 -4.48% 7,357
10/26/10 CA$5.580 +7.93% 14,492
09/26/09 CA$5.170 -1.90% 6,875
08/26/08 CA$5.270 +7.11% 22,074
07/26/07 CA$4.920 -1.60% 6,434

Quarterly revenue - Rate of surprise